NCT03496168

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).

Conditions

• Hypertrophic Cardiomyopathy

Interventions

Type	Name	Description
DRUG	mavacamten	mavacamten capsules

Timeline

• Start date: 2018-04-26
• Primary completion: 2023-11-09
• Completion: 2023-11-09
• First posted: 2018-04-12
• Last updated: 2025-01-09
• Results posted: 2025-01-09

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study